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Microﬂuidics in coagulation monitoring devices:
a mini review
Leanne F. Harris

*a and Anthony J. Killard

b

Diagnosis and monitoring of disorders of coagulation and disturbances in haemostasis has been around for
many years. Thrombotic and bleeding disorders are amongst the leading causes of mortality in the
developed world, thus driving research in this area. The simplicity with which miniaturised devices
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operate and their application to the study of coagulation and haemostasis oﬀer potential advantages
over traditional testing, such as improvements in clinical decision making and ultimately patient care.

DOI: 10.1039/c8ay01230j

This review looks at progress in microﬂuidic device development in the ﬁeld of haemostasis and

rsc.li/methods

coagulation biology.

Introduction
Microuidic devices allow for the identication of a range of
diagnostic targets inclusive of metabolites, proteins, nucleic
acids, cells and pathogens.1 The application of miniaturised
point of care (POC) technologies is well established in coagulation and haemostasis. Commercial devices in this space have
focused on monitoring of anticoagulant therapies to target
bleeding and thrombotic disorders and have successfully
contributed to the point-of-care testing (POCT) market, which
was estimated to be worth approximately US $5.6 billion in
2011.2 In contrast, microuidic research in this area is focused
on the measurement of platelet activity and the identication of
coagulation proteins to aid in the study of blood function to
inform clinical decisions around haemostatic disorders.1,3
Microuidics involves the handling of small volumes of
liquid within channels that are mere micrometres (10–100 mm)
in dimension.4 The major advantages of these miniaturised
devices include low cost due to the use of disposable materials,
rapid turnaround times, and enhanced sensitivity and specicity.1,4 The low-cost aspect of these technologies is in part
related to the type of material used for their fabrication, which
can range from polymer or plastic substrates to paper.5,6 There
is also a transition away from large scale clean room fabrication
methodologies, in preference for low-cost equipment such as
laser cutters and 3-D printers, that are highly compatible for the
manufacture of paper or plastic chips. This presents the life
science community with opportunities to exploit lab on a chip
(LOC) technologies for high throughput analysis of biological
samples, that were previously limited or even inaccessible.5
a
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The biology of blood coagulation is not without complexity
involving a range of clotting proteins, each exerting their
eﬀect in the next step of the clotting cascade.7 Divided into
two key pathways, the intrinsic pathway is activated by
damaged vessels that expose negatively charged activators
causing the sequential activation of clotting factor proteins. It
is this activation of clotting factors that ultimately results in
the formation of a brin clot. The alternative extrinsic
pathway results from damage to the endothelium releasing
tissue factor, the trigger for platelet activation and brin
polymerisation.7,8
It is these pathways that are targeted by the traditional clotbased assays such as the prothrombin time (PT), an assay that
measures the length of time it takes for clot formation through
the extrinsic pathway. The activated partial thromboplastin
time (aPTT) and activated clotting time (ACT) tests replicate
clotting via the intrinsic pathway. While the thrombin clotting
time (TCT) involves the addition of excess thrombin to a sample
in vitro to stimulate clot formation.9
POC technology oﬀers the opportunity to evaluate and
monitor the complexity of the coagulation pathways. As outlined by Lancé the ideal coagulation test should be a reliable,
rapid and easy to perform test that gives an accurate indication
of the risk of bleeding or clotting.10 Researchers can monitor
blood in vitro, blood ow under normal conditions and blood
ow in an activated sample where coagulation has been
imitated, thus mimicking thrombotic events. Innovation in
channel design and geometry and manipulation of channel
dimensions have allowed for enhanced insight into the complex
process of blood coagulation.3,11 The majority of monitoring
devices on the market do not account for the dynamics of blood
ow, which is a signicant contributor to platelet function and
thrombosis.12 However a number of devices in the literature
report their incorporation of shear force into their devices to
mimic the blood ow of arteries and vessels. They achieve this
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imitation of in vivo vessel dynamics through the use of ow
chambers with syringe pumps or plate rollers.11–15
In this review we present a snapshot of recent and current
microuidic technologies reported in the literature, that focus
on the incorporation of assays specic for the study of haemostasis and coagulation. The devices reported include assays that
concentrate, not only on newer methods for monitoring inhibitors of clotting, but microuidics that can demonstrate the
physical process of clot formation, tests that yield information
on the mechanisms of platelet function, and clotting factor
assays that unearth how individual proteins are impacted in
haemostatic disorders.

Microﬂuidics for anticoagulant
monitoring
The demand for POC devices in coagulation testing was
prompted by the need for anticoagulant monitoring aer
surgery.16 The rapid turnaround times achieved with POC
devices compared to conventional benchtop instruments played
a signicant role in their commercial success, due to the ease
with which they could be implemented into emergency room
settings and conveniently at the patient's bedside.
Microuidic devices commonly used in the management of
anticoagulant therapy incorporate the traditional assays as
aforementioned such as the PT, aPTT, ACT and TCT.17 The
shortcomings of conventional clot-based assays have been
reviewed extensively in the literature, in that they do not accurately reect the entire clotting process, rather one particular
point in the cascade, which is the time to clot formation.10 Clotbased assays are also renowned for their inter-laboratory variability and limited ranges of measurement.18–20
They did however contribute to our understanding of the
clotting process and their simple mode of operation positioned
them as the ideal candidates for transition into automated
laboratory coagulation analysers and subsequently into miniaturised POC devices.
Commercially available microuidic assays incorporating
these conventional clotting assays include the HemoSense
INRatio PT/INR system (HemoSense Inc.) which uses electrochemical impedance to measure clotting between printed
electrodes on a disposable polymer strip.21 The i-STAT (Abbott)
is another electrochemical impedance-based device used to
measure PT and ACT.2 The Xprecia Stride® Coagulation Analyser (Siemens Healthcare GmbH) uses electrochemical technology and amperometry for the detection of thrombin activity
and has received plaudits for its high quality and innovative
ergonomic design.22 The combined eﬀect of mechanical and
electrochemical detection is also observed in several microuidic devices on the market that ultimately measure brin
formation.9
Optical detection is another method used for the measurement of clotting time in response to anticoagulation. For
example, prior to the development of the Coaguchek XS (Roche
Diagnostics International Ltd.), which is an electrochemical
impedance-based device, the CoaguChek S (Roche Diagnostics
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International Ltd.) incorporated iron lings into a strip that
interacted with an electromagnetic eld. The lings oscillated
until clot formation whereby movement ceased which was
detected optically to return the clotting time.23 Other devices
that followed suit included Hemochron (ITC), ProTime (ITC)
and GEM PCL (Instrumentation Laboratory) to name but a few.9
The devices outlined above are targeted towards monitoring
anticoagulant therapies such as warfarin (vitamin K antagonist), unfractionated heparin (UFH) or low molecular weight
heparin (LMWH). The assays incorporated into these miniaturised devices trigger the intrinsic or extrinsic pathways
which involve many clotting proteins, resulting in variable
results. The traditional anticoagulant drugs themselves suﬀer
from drawbacks. Anticoagulation with vitamin K antagonists
such as warfarin, is reported to be beyond the therapeutic range
almost 50% of the time.24 While heparins, known for their
narrow therapeutic windows and unpredictable dose response
proles, can return shortened or prolonged clot times leading to
over- or under-dosing of patients.25 As a result, more specic
targeted assays are required that do not measure the entire
clotting cascade.
A polymer microuidic device was reported in the literature that monitors UFH and LMWH therapy by targeting
factor Xa (FXa).18 FXa is a coagulation protein that is at
a critical position in the cascade where the intrinsic and
extrinsic pathways meet.26,27 The disposable laminated
microuidic chip (Fig. 1) uses uorescence detection, capillary ll of the sample, a volume of 10 ml and a result is
returned within 60 seconds. A major advantage of this technology is the measurement of FXa, which bypasses the
intrinsic and extrinsic pathways in the measurement of anticoagulant eﬀect, thereby enhancing specicity.
UFH has been on the market for many years, but it presents
with unpredictable pharmacokinetics and pharmacodynamics.26 As a result pharmaceutical companies are taking
advantage of the gap in the market and are driving the development of more specic inhibitors of clotting proteins, which
include thrombin or factor IIa (FIIa) and FXa.28 While these
newer drugs may oﬀer improvements in sensitivity and
predictability thus minimising the need for monitoring, it will

Fig. 1 Schematic and photograph of the microﬂuidic anti-Xa assay
device (reproduced with permission, Harris et al. 2013, RSC).18
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always be required for certain patient cohorts where complications exist.24,25
Inhibitors of FXIIa and FXIa have also been recommended
for inhibition of thrombosis with a microuidic device that
operates on the principle of contact activation of coagulation.13,29 An eight-channel device comprised of PDMS (poly(dimethylsiloxane)) was coated with collagen bound to kaolin
for activation of the intrinsic pathway. PDMS, an organic polymer is exible, biocompatible and confers excellent optical
properties.2 Thrombus structure including platelet and brin
formation was observed on-chip. Platelet inhibitors (MRS 2197
and 2-MeSAMP) reduced platelet and brin deposition, indicating potential for application to studies of FXIIa/FXIa
antithrombotics which may oﬀer enhanced specicity over
traditional drugs in the future.13

Haemostasis ‘on a chip’
Recent research in this area reveals a move away from the
conventional clotting time assays for the reasons previously
outlined. More specic and detailed analysis of the haemostatic
system is required to better understand disorders of coagulation including those disorders resulting from factor
deciencies.
A recent PDMS microchip (Fig. 2) was used to demonstrate
the impact of tissue factor (FVII/IIa) on blood clot formation
and blood ow. Through manipulation of tissue factor localisation and surface density within the device, platelet deposition, thrombin generation, and brin accumulation were
analysed. Due to the additional computational modelling
carried out, valuable insights were gained into the role of TF in
clot formation and resistance to blood ow.30
Real-time monitoring of haemostasis using a 12-channel
PDMS chip to mimic small blood vessels was also presented by
Jain et al. who additionally indicated that shear gradient as
opposed to shear rate was responsible for activation of the
clotting process.12 With the incorporation of mathematical
modelling, the antithrombotic eﬀects were observed in realtime, ideal for application to hospital and clinical settings.
Microuidic devices for cell selection and sorting, in
particular for whole blood samples where there is oen the
requirement to separate red blood cells (RBCs) from plasma
(oen by centrifugal sedimentation) have been reported extensively in the literature.1,31–33 In line with this, blood screening

Photographic (A) and 2-D schematic (B) representation of
PDMS microﬂuidic device used in the determination of blood clot
structure and resistance under venous shear (reproduced with
permission, Govindarajan et al. 2017, Cell Press).30
Fig. 2
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Fig. 3 Suspension of PBS (phosphate buﬀered saline) with ﬂuorescent
beads to illustrate the structure of the microﬂuidic herringbone mixer
with (A) and without (B) herringbone features (reproduced with
permission, Lehmann et al. 2018, AIP Publishing).63

has also been adapted into a simple paper-based POC assay that
incorporates sample separation. The porous cellulose
membrane separates plasma from the red blood cells and the
colour of the RBCs is used to indicate whether the patient falls
within the recommended range for their condition.34
Within haemostasis research there is a drive to develop
assays that focus on the global measurement of coagulation.
Viscoelastic tests such as thromboelastography (TEG) and
thromboelastometry (ROTEM) are techniques that result in
tracings that reect the development of a blood clot over time.10
Using oscillating sheer force these techniques generate more
specic and detailed information on both the clotting process
and brinolysis, than the traditional clot-based assays.9,35 The
TEG® Platelet Mapping™ assay (Haemonetics® Corporation)
uses small volumes of blood, while measuring both clot
strength and platelet function in patients who are at cardiovascular risk.36 For the treatment of postoperative bleeding aer
cardiac surgery, TEG and ROTEM have been recommended due
to their minimal blood requirement, assay versatility and their
contribution to rapid clinical decision making.37
ClotChip is a microuidic device reported recently in the
literature as being capable of capturing the dynamics of the
clotting process using dielectric spectroscopy.38 Interestingly,
the authors compared their results to ROTEM producing
a strong positive correlation, indicating signicant potential for
monitoring the overall clotting process, rendering it a global
assay of haemostasis.
Quartz crystal microbalances (QCM) have featured signicantly within the group of technologies that can provide global
measurements of haemostasis. They are resonator-based
methods that can detect physical changes at its surface. Due
to this property and its ultrasensitivity, QCM has been used
historically to measure of the mass of lms or substances
attached to its surface.39 It has an additional feature, in that it
can measure the viscoelasticity of the target substance at its
surface.40
QCM has been used in conjunction with standard clot-based
assays (PT, aPTT and TCT).39,41–43 While the tests used act as
activators of clotting, it is the QCM interface that allows for
detailed analysis of the mechanics and kinetics of clot
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formation. Additional information on brin bre diameter and
bre density, which correlates to the rate of clot formation, can
also be elucidated using QCM, yet another benet of this
increasingly popular next-generation technology.44
Sinn et al. employed QCM methodologies to establish
a platelet aggregation assay with signicant diﬀerences in
platelet aggregation observed in both uncoated and brinogen
coated sensors.45 With further development QCM could prove
a useful alternative to platelet aggregometry.
Applications of QCM with dissipation (QCM-D) to anticoagulant monitoring has been highlighted in the literature.46 QCMD and aPTT analysis of samples from patients receiving dabigatran was carried out, returning good correlations (R2 ¼ 0.99)
between the two methods. QCM-D oﬀers an ultrasensitive
method for monitoring the patient response to oral anticoagulant therapy.

Factor speciﬁc assays
Assays that allow for targeting specic coagulation factors
aﬀord the opportunity to study the specic roles of clotting
proteins in the haemostatic process. Additionally, they yield
insight into the behaviours of clotting proteins in diseased
states. Specic targets for POC development are not exclusive to
clotting factors such as thrombin and brinogen but also
include brinolytic products such as D-dimer or brinogen
degradation products (FDPs), important in diagnosing thrombotic events or disseminated intravascular coagulation (DIC).9
Thrombin is a popular target in coagulation research. A
nanochannel device using a nanoporous membrane on chip
was reported as successfully measuring thrombin within clinically relevant picomolar ranges.47 The device incorporated
aptamer/thrombin recognition, which presents with signicant
advantages due to the high aﬃnity and stability associated with
these synthetic nucleic acid sequences. Voltammetric
measurement was then employed for the diagnosis of coagulation abnormalities.
Other label-free biosensors for thrombin detection that
incorporate aptamers, use poly(pyrrole-nitrilotriacetic acid)48
lms and indium tin oxide substrates49 which show excellent
thrombin binding. These high-performance sensors, or aptasensors, provide opportunities to detect thrombin in whole
blood with a knock-on eﬀect for disease diagnosis.
Immunoassays are typically employed to detect D-dimer,
protein S and antithrombin.50 D-dimer and FDPs are indicative of clot dissolution and the breakdown of brin and are used
in the diagnosis of disorders of the brinolytic system. One
such POC D-dimer assay, (ACQT90 Flex D-dimer) reported by
Sidelmann et al. uses uorescence and D-dimer antibody
binding to determine its concentration in whole blood.51 A
comparison of the eﬀectiveness of ve diﬀerent commercially
available D-dimer assays was executed by Geersing et al. who
reported high sensitivities for all assays analysed and recommended their suitability for incorporation into the GP setting
for exclusion of venous thrombosis.52 These devices incorporate
tests ranging from immunochromatography to enzyme-based
immunoassays.
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Platelet function assays
Platelets aggregate at a site of injury to form a primary platelet
plug, in what can be described as a multi-step process, prior to
thrombin generation and the formation of the haemostatic
plug.7 It is the exposure of various subendothelial factors
(collagen, laminin, brinogen) that promote platelet adhesion.53,54 Some important features of platelet adhesion include
the shear rate within the blood vessels and the release of the
glycoprotein von Willebrand factor (VWF). Under high shear, it
is VWF that promotes platelet clumping.54
Disorders that arise due to platelet abnormalities include
thrombocythemia, thrombocytosis and thrombocytopenia.55
Platelet function assays are used to assess abnormalities in
platelet adhesion, which is central in the response to vessel
damage, in addition to monitoring the eﬃcacy of various antiplatelet drugs such as aspirin, or glycoprotein IIb/IIIa inhibitors. The importance of these assays is increasing due to the
increasing number of patients on anti-platelet therapy that
present with a high risk of bleeding.56 Li et al. present a nice
review of the platelet response to a range of pharmacological
agents in whole blood on microuidic platforms.57
Microuidics is emerging as a key player in current research
around platelet function biology due to its controlled hemodyanmics.57,58 Schoeman et al. report a PDMS-based microuidic model of haemostasis, whereby thrombus formation is
mimicked within the channel. The impact of the antiplatelet
P2Y12 receptor inhibitor on platelet activation was also determined, indicating the potential of such a device in the analysis
of antiplatelet eﬀects.59 The platelet response to Abciximab,
another anti-platelet drug, was analysed in a well-plate microuidic device that also accounted for shear ow, yielding a more
realistic insight into platelet aggregation.60
The clinical impact of microuidic devices has also been
reported in the literature with many devices reporting on their
use with samples from haemophiliac patients, reecting real
world applications. Measuring platelet deposition and brin
formation, the collagen coated devices range from hard plastic61
to so lithography generated PDMS chips,58,62 emphasising low
cost and easy fabrication methodologies.
Innovative designs that improve upon previous iterations of
devices are also prevalent in the literature. One such device
incorporates a herringbone mixer on-chip to allow for recalcication of citrated whole blood, eliminating the preprocessing step. The mixer does not cause platelet activation,
thus thrombus formation can be monitored for up to 30
minutes, to gain extra patient data, compared to standard ow
assays that can only be visualised for 3–10 minutes (Fig. 3).63

Conclusions
The rate at which microuidics research is advancing is
impressive. Simple, low-cost tools and materials (plastics and
paper) are the current trends in this space. And combined with
low cost readers (smartphones, LEDs, CCD cameras) they
become an attractive package for POCT. Makerspacers have
recently been described as facilitators in the application of
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microuidics to the life sciences, opening up opportunities that
will ameliorate the success of the transition of POC devices to
market.5 These physical spaces provide improved access to lowcost fabrication technologies that encourage microdevice
development for biological applications.
The optimisation and subsequent validation of POC technology does present challenges in terms of performance characteristics such as sensitivity, specicity and reproducibility
and operational characteristics including initial cost and assay
stability. As with any new medical device issues around clinical
acceptance and adoption into practice will depend on economic
factors such as patient demand.9 Technologies in POCT are
developing rapidly, with state-of-the art and ingenious concept
designs. The injection of such technologies onto the commercial market does however present with challenges. Barriers
include the slow transition of these microdevices within the
small research laboratory to large scale mass production, the
quality of mass produced devices, and the associated cost of
upscaling these technologies.2 Government regulation and
issues around intellectual property also feature as potential
barriers to commercialisation.9
Innovative materials such as nanoparticles, nanostructures
and nanowires for device development, nanoparticle and labelfree detection of biomolecules are just a snapshot of what we
can expect to see in future miniaturised devices.64 What
emerges from the literature around coagulation microuidics is
the absence of (1) a robust global assay of haemostasis and (2)
a coagulation device that oﬀers multiplexing. POC multiplex
haematology would oﬀer clinicians eﬃciency and convenience,
while improving patient outcomes at the point-of-care.65 Incremental improvements in assay and technology development, as
outlined in this review, can only prove benecial to the haemostasis and coagulation community.
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10 M. D. Lancé, Thromb. J., 2015, 13, 1–6.

3718 | Anal. Methods, 2018, 10, 3714–3719

Minireview

11 J. Zilberman-Rudenko, J. Sylman, H. Lakshmanan,
O. McCarty and J. Maddala, Cell. Mol. Bioeng., 2017, 10,
16–29.
12 A. Jain, A. Graveline, A. Waterhouse, A. Vernet,
R. Flaumenha and D. E. Ingber, Nat. Commun., 2016, 7,
1–10.
13 S. Zhu and S. L. Diamond, Thromb. Res., 2014, 134, 1335–
1343.
14 B. R. Branchford, C. J. Ng, K. B. Neeves and J. Di Paola,
Thromb. Res., 2015, 136, 13–19.
15 T. V. Colace, P. F. Fogarty, K. A. Panckeri, R. Li and
S. L. Diamond, J. Thromb. Haemostasis, 2014, 12, 147–158.
16 A. St. John, in Point of Care Testing, ed. C. P. Price, A. St. John
and J. M. Hicks, American Association for Clinical Chemistry
Inc., Washington, USA, 2nd edn, 2004, pp. 31–45.
17 M. J. Pugia and C. P. Price, in Point of Care Testing, ed. C. P.
Price, A. St. John and J. M. Hicks, American Association for
Clinical Chemistry Inc., Washington, USA, 2nd edn, 2004,
pp. 13–30.
18 L. F. Harris, P. Rainey, V. Castro-López, J. S. O'Donnell and
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